Page last updated: 2024-12-07

norbuprenorphine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Norbuprenorphine is a synthetic opioid analgesic with a complex chemical structure. It is a derivative of buprenorphine, a partial opioid agonist, and exhibits unique pharmacological properties. It is studied for its potential therapeutic applications in pain management, opioid dependence treatment, and other medical conditions. Research on norbuprenorphine focuses on its efficacy, safety, and potential advantages over existing opioid medications. The compound is typically synthesized through multi-step chemical reactions involving buprenorphine as a starting material.'

norbuprenorphine: metabolite of buprenorphine found in urine & feces; RN given refers to (5alpha,7alpha)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID114976
CHEMBL ID1743323
CHEBI ID172315
SCHEMBL ID14408877
MeSH IDM0128169

Synonyms (25)

Synonym
(1s,2s,6r,14r,15r,16r)-16-[(2s)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
CHEBI:172315
norbuprenorphine
6,14-ethenomorphinan-7-methanol, alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphas,5alpha,7alpha)-
6,14-ethenomorphinan-7-methanol, alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, [5alpha,7alpha(s)]-
des(cyclopropylmethyl)buprenorphine
6,14-ethenomorphinan-3-ol, 4,5-epoxy-18,19-dihydro-18-[(1s)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-, (5alpha,6beta,14beta,18r)-
78715-23-8
6,14-ethenomorphinan-7-methanol, alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphas,5alpha,7alpha)- (9ci)
CHEMBL1743323
unii-7e53b4o073
7e53b4o073 ,
buprenorphine hydrochloride impurity b
buprenorphine impurity b
(alphas,5alpha,7alpha)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol
(2s)-2-(4,5.alpha.-epoxy-3-hydroxy-6-methoxy-6.alpha.,14-ethano-14.alpha.-morphinan-7.alpha.-yl)-3,3-dimethylbutan-2-ol
YOYLLRBMGQRFTN-IOMBULRVSA-N
SCHEMBL14408877
norbuprenorphine 0.1 mg/ml in methanol
norbuprenorphine 1.0 mg/ml in methanol
(2s)-2-(4,5alpha-epoxy-3-hydroxy-6-methoxy-6alpha,14-ethano-14alpha-morphinan-7alpha-yl)-3,3-dimethylbutan-2-ol (norbuprenorphine)
DTXSID60891436
Q63396332
norbuprenorphine, 0.1mg/ml in methanol
norbuprenorphine, 1mg/ml in methanol

Research Excerpts

Overview

Norbuprenorphine is a major metabolite of buprenorphines. It is a potent agonist of opioid receptors. In the mouse writhing test, it provides antinociceptive efficacy similar to bupenorphine.

ExcerptReferenceRelevance
"Norbuprenorphine is a major metabolite of buprenorphine and potent agonist of μ, δ, and κ opioid receptors. "( P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception.
Brown, SM; Campbell, SD; Crafford, A; Holtzman, MJ; Kharasch, ED; Regina, KJ, 2012
)
2.09
"Norbuprenorphine is a likely contributor to the overall pharmacology of buprenorphine; in the mouse writhing test, norbuprenorphine provides antinociceptive efficacy similar to buprenorphine, with analgesic activity shown to be dose-dependent."( Buprenorphine: new pharmacological aspects.
Cowan, A, 2003
)
1.04

Actions

ExcerptReferenceRelevance
"Norbuprenorphine did not inhibit the metabolism of flunitrazepam or omeprazole. "( Lack of interaction of buprenorphine with flunitrazepam metabolism.
Kilicarslan, T; Sellers, EM, 2000
)
1.75

Toxicity

ExcerptReferenceRelevance
" No serious adverse events (AEs), nor "severe" AEs, although more AEs and Treatment-Emergent AEs with "bup-lyo" (mostly "mild")."( Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study.
Baillie, S; Beavan, P; Bell, J; Bogdanowicz, K; Keen, J; Knight, A; Reed, K; Strang, J; van der Waal, R, 2017
)
0.46

Pharmacokinetics

The pharmacokinetic characteristics of buprenorphine (BN) and its active metabolite, norbuprenorphines (NBN), was investigated using rats. The terminal elimination half-life of norb uprenorphin was longer than buprengnorphine.

ExcerptReferenceRelevance
"The pharmacokinetic characteristics of buprenorphine (BN) and its active metabolite, norbuprenorphine (NBN), was investigated using rats."( Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats.
Iga, T; Kotaki, H; Ohtani, M; Sawada, Y; Uchino, K,
)
0.57
" The terminal elimination half-life of norbuprenorphine was longer than buprenorphine."( Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
Darwin, WD; Kuhlman, JJ; Lalani, S; Levine, B; Magluilo, J, 1996
)
0.56
" Noncompartmental and compartmental methods were used to perform pharmacokinetic data analysis."( Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine.
Cowan, A; Gopal, S; Tzeng, TB, 2002
)
0.56
" These data were fitted to physiologically based pharmacokinetic models."( Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model.
Foster, D; Grant, C; Jensen, ML; Martinez, A; Somogyi, A; Upton, R, 2007
)
0.58
"006 mg kg(-1)) and pharmacokinetic parameters were determined for each route of administration using a noncompartmental model."( Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site.
Barlow, BM; Davis, JL; LaFevers, DH; Messenger, KM; Posner, LP, 2011
)
0.37
"Buprenorphine has a long plasma half-life and results in plasma concentrations that are consistent with analgesia in other species for up to 4 hours following IV administration of this dose in horses."( Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site.
Barlow, BM; Davis, JL; LaFevers, DH; Messenger, KM; Posner, LP, 2011
)
0.37
" Pharmacokinetic profiles of buprenorphine, norbuprenorphine, and naloxone were measured over the 24-hour dosing interval on day -1 (buprenorphine/naloxone alone, reference) and day 7 of telaprevir coadministration (test)."( Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy.
Garg, V; Luo, X; Smith, F; Trevejo, J; van Heeswijk, RP, 2012
)
0.64
"Prescribed sublingual (SL) buprenorphine is sometimes diverted for intravenous (IV) abuse, but no human pharmacokinetic data are available following high-dose IV buprenorphine."( Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.
Cone, EJ; Huestis, MA; Pirnay, SO; Preston, KL; Umbricht, A, 2013
)
0.68
" Thus, previously demonstrated pharmacodynamic ceiling effects (over 2-16 mg) are not due to pharmacokinetic adaptations within this range, although they may play a role at doses higher than 12 mg."( Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.
Cone, EJ; Huestis, MA; Pirnay, SO; Preston, KL; Umbricht, A, 2013
)
0.68
"A population pharmacokinetic model was developed using 36 opioid-dependent subjects who received single subcutaneous doses of RBP-6000."( A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence.
Fudala, PJ; Gomeni, R; Greenwald, MK; Heidbreder, C; Nasser, AF; Zheng, B, 2014
)
0.4
"The resulting pharmacokinetic model accurately described buprenorphine and norbuprenorphine plasma concentrations."( A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence.
Fudala, PJ; Gomeni, R; Greenwald, MK; Heidbreder, C; Nasser, AF; Zheng, B, 2014
)
0.63
" Serial blood samples were taken for pharmacokinetic analysis."( Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy.
Adeniji, A; Elgadi, M; Huang, F; Joseph, D; Riesenberg, RR; Schobelock, MJ; Vince, BD; Webster, LR, 2015
)
0.42
" This study aimed to establish the pharmacokinetic parameters of a single subcutaneous dose of sustained release buprenorphine (Buprenorphine SR) in juvenile northern elephant seals (Mirounga angustirostris) with regard to its potential to provide long-lasting analgesia that requires infrequent dosing."( Pharmacokinetics of a single subcutaneous dose of sustained release buprenorphine in northern elephant seals (Mirounga angustirostris).
Barbosa, L; Chinnadurai, SK; Johnson, S; Knych, HK; Molter, CM; Wack, RF, 2015
)
0.42
" Two open-label studies were performed to determine the pharmacokinetic profile of buprenorphine from buccal film formulations of buprenorphine."( Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.
Bai, SA; Finn, A; Xiang, Q, 2016
)
0.43
" These pharmacokinetic results suggest that therapeutic buprenorphine plasma concentrations can be obtained with BBUP across a wide dose range in a shorter time than other (eg, transdermal) dosage forms."( Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.
Bai, SA; Finn, A; Xiang, Q, 2016
)
0.43
"The pharmacokinetic profiles of CAM2038 q1w and q4w versus sublingual buprenorphine support expected treatment efficacy with once-weekly and once-monthly dosing, respectively."( Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
Albayaty, M; Johnsson, M; Linden, M; Olsson, H; Strandgården, K; Tiberg, F, 2017
)
0.46
" A bespoke bicompartmental pharmacokinetic model simultaneously fitted data from two analytes/three routes of administration."( Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats.
Beaudry, F; Benito, J; Doodnaught, GM; Edge, D; Monteiro, BP; Pelligand, L; Steagall, P, 2017
)
0.46
"The SC administration of Simbadol™ was characterized by prolonged absorption half-life and sustained plasma concentrations yielding long-lasting antinociception (≥ 24 hours) when compared with the IV and OTM routes."( Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats.
Beaudry, F; Benito, J; Doodnaught, GM; Edge, D; Monteiro, BP; Pelligand, L; Steagall, P, 2017
)
0.46
" Pharmacokinetic parameters were calculated using non-compartmental analysis."( Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
Dong, R; Gray, F; Jiang, J; Laffont, CM; Lang, L; Learned, SM; Li, D; Liu, Y; Liu, Z; Wang, H; Young, M, 2019
)
0.51
"The pharmacokinetic profiles of buprenorphine and naloxone were consistent between single- and multiple-dose studies."( Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
Dong, R; Gray, F; Jiang, J; Laffont, CM; Lang, L; Learned, SM; Li, D; Liu, Y; Liu, Z; Wang, H; Young, M, 2019
)
0.51
"The present data suggest that buprenorphine/naloxone pharmacokinetic profiles in Chinese participants are consistent, overall, with those in Western populations, supporting no differences in dosing."( Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
Dong, R; Gray, F; Jiang, J; Laffont, CM; Lang, L; Learned, SM; Li, D; Liu, Y; Liu, Z; Wang, H; Young, M, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
" Daclatasvir is a potent pangenotypic inhibitor of the HCV NS5A replication complex recently approved for HCV treatment in Europe and Japan in combination with other antivirals."( Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.
Bertz, R; Bifano, M; Bruce, RD; DeMicco, M; Garimella, T; Hwang, C; Kandoussi, H; Luo, WL; Wang, R; Wastall, P, 2015
)
0.42
" We determined the whole blood pharmacokinetics of ethanol (using gas chromatography coupled to mass spectrometry), BUP and its metabolites (using liquid chromatography coupled to tandem mass spectrometry) and investigated the mechanisms of drug-drug interactions in the presence or absence of naloxone (7."( Editor's Highlight: Neurorespiratory Effects of Buprenorphine and Ethanol in Combination: A Mechanistic Study of Drug-Drug Interactions in the Rat.
Chevillard, L; Cohier, C; Mégarbane, B; Risède, P; Roussel, O; Salle, S, 2017
)
0.46
" Subjects received methadone (arm 1) or buprenorphine-naloxone (arm 2) once daily (QD) per their existing individual prescriptions alone (days 1 to 9) and then in combination with glecaprevir at 300 mg QD and pibrentasvir at 120 mg QD (days 10 to 16) each morning."( No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Asatryan, A; Geoffroy, P; Kort, J; Kosloski, MP; Liu, W; Zhao, W, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" This study compared the relative buprenorphine bioavailability of these different formulations."( Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.
Bigelow, GE; Moody, DE; Stoller, KB; Strain, EC; Walsh, SL, 2004
)
0.32
"These results suggest there may be greater bioavailability of buprenorphine/naloxone versus buprenorphine alone tablets, and that the bioavailability of buprenorphine from the former is very similar to that seen with solution after 2 weeks of stabilization on each formulation."( Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.
Bigelow, GE; Moody, DE; Stoller, KB; Strain, EC; Walsh, SL, 2004
)
0.32
"The absolute bioavailability of BBUP was 46% to 51% across a 16-fold dose range, with dose-proportional increases in systemic exposure."( Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.
Bai, SA; Finn, A; Xiang, Q, 2016
)
0.43
" PK found greater bioavailability of buprenorphine with "bup-lyo" (but not norbuprenorphine)."( Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study.
Baillie, S; Beavan, P; Bell, J; Bogdanowicz, K; Keen, J; Knight, A; Reed, K; Strang, J; van der Waal, R, 2017
)
0.69
" PK found substantially increased bioavailability of buprenorphine (but not of nor-buprenorphine) with "bup-lyo" relative to "bup-SL."( Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study.
Baillie, S; Beavan, P; Bell, J; Bogdanowicz, K; Keen, J; Knight, A; Reed, K; Strang, J; van der Waal, R, 2017
)
0.46
" Bioavailability for SC and OTM was 94% and 24%, respectively."( Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats.
Beaudry, F; Benito, J; Doodnaught, GM; Edge, D; Monteiro, BP; Pelligand, L; Steagall, P, 2017
)
0.46

Dosage Studied

Pharmacokinetic profiles were measured over the 24-hour dosing interval on day -1 (buprenorphine/naloxone alone, reference) and day 7 of telaprevir coadministration (test) Study was performed to determine if buprenmorphine (BPR) and norbuprene (NBPR) could be detected in human hair after controlled administration of drug.

ExcerptRelevanceReference
" The urinary and fecal excretion pattern observed for a human subject following oral dosing of buprenorphine suggests enterohepatic circulation of buprenorphine."( 63Ni electron-capture gas chromatographic assay for buprenorphine and metabolites in human urine and feces.
Cone, EJ; Darwin, WD; Gorodetzky, CW; Yousefnejad, D, 1985
)
0.27
" Results suggest that a dose-response relationship exists between the concentration of buprenorphine in hair and the administered dose."( Hair analysis for buprenorphine and its dealkylated metabolite by RIA and confirmation by LC/ECD.
Cirimele, V; Edel, Y; Jamey, C; Kintz, P; Mangin, P, 1994
)
0.29
" Group 2 subjects received alternate-day dosing of buprenorphine and placebo on days 19 to 36."( Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine.
Cone, EJ; Fudala, PJ; Johnson, RE; Kuhlman, JJ; Levine, B, 1998
)
0.57
" Intravenous injection of crushed tablets, a concomitant intake of psychotropics (especially benzodiazepines), and the high dosage of the BUP formulation available in France appear to be the major risk factors for such fatalities."( Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities.
Kintz, P; Ludes, B; Tracqui, A, 1998
)
0.3
" This study was performed to determine if buprenorphine (BPR) and norbuprenorphine (NBPR) could be detected in human hair after controlled administration of drug and to determine if segmental analysis of hair was an accurate record of the dosing history."( A retrospective study of buprenorphine and norbuprenorphine in human hair after multiple doses.
Cone, EJ; Krueger, GG; Mizuno, A; Rollins, DE; Valdez, AS; Wilkins, DG, 1999
)
0.8
"Buprenorphine at high dosage became available in France in 1996, as a substitution treatment for heroin addicts."( A new series of 13 buprenorphine-related deaths.
Kintz, P, 2002
)
0.31
"IV injection of crushed tablets, a concomitant intake of psychotropics (especially benzodiazepines and neuroleptics) and the high dosage of the buprenorphine formulation available in France appear as the major risk factors for such fatalities."( A new series of 13 buprenorphine-related deaths.
Kintz, P, 2002
)
0.31
" Early pharmacological studies demonstrated buprenorphine's strong binding to opioid receptors, and an inverted U-shaped dose-response curve in rodents."( Buprenorphine: new pharmacological aspects.
Cowan, A, 2003
)
0.32
" Randomized animals in 4 groups received sequential intraperitoneal dosing with: (dexamethasone [days 1-3]+buprenorphine [day 4]), (dexamethasone solvent [days 1-3]+buprenorphine [day 4]), (dexamethasone [days 1-3]+buprenorphine solvent [day 4]), or (dexamethasone solvent [days 1-3]+buprenorphine solvent [day 4])."( Dexamethasone hepatic induction in rats subsequently treated with high dose buprenorphine does not lead to respiratory depression.
Baud, FJ; Borron, SW; Descatoire, V; Hreiche, R; Mégarbane, B; Milan, N; Monier, C; Pessayre, D; Pirnay, S; Risède, P, 2006
)
0.33
" Urine samples were collected prior to dosing and at 2, 4, 6, 8 12, 24, 48, 72, and 96 h post-dose."( Urinary detection times and metabolite/parent compound ratios after a single dose of buprenorphine.
Ahlner, J; Andersson, M; Gunnarsson, L; Hägg, S; Josefsson, M; Kronstrand, R; Nyström, I, 2008
)
0.35
" The developed method can be used in routine every day analysis by clinical and forensic laboratories, for pharmacokinetic studies, for therapeutic drug level monitoring in order to adjust BPN dosage of BPN maintained patients or for the investigation of forensic cases."( Development and validation of a highly sensitive GC/MS method for the determination of buprenorphine and nor-buprenorphine in blood.
Athanaselis, SA; Maravelias, CP; Nikolaou, PD; Papoutsis, II; Pistos, CM; Spiliopoulou, CA, 2011
)
0.37
" Pharmacokinetic profiles of buprenorphine, norbuprenorphine, and naloxone were measured over the 24-hour dosing interval on day -1 (buprenorphine/naloxone alone, reference) and day 7 of telaprevir coadministration (test)."( Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy.
Garg, V; Luo, X; Smith, F; Trevejo, J; van Heeswijk, RP, 2012
)
0.64
" Although individual data showed moderate variability in the exposures between subjects and treatments, there was no evidence of symptoms of opiate overdose or withdrawal either during the coadministration of faldaprevir with methadone or buprenorphine-naloxone or after faldaprevir dosing was stopped."( Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy.
Adeniji, A; Elgadi, M; Huang, F; Joseph, D; Riesenberg, RR; Schobelock, MJ; Vince, BD; Webster, LR, 2015
)
0.42
"5, 1, 2, and 24 hours after dosing in subjects with confirmed cocaine use and abstinence."( The impact of recent cocaine use on plasma levels of methadone and buprenorphine in patients with and without HIV-infection.
DInh, AT; Fiellin, DA; Fiellin, LE; Lruie, BS; McCance-Katz, EF; Moody, DE; Tetrault, JM, 2015
)
0.42
" These pharmacokinetic results suggest that therapeutic buprenorphine plasma concentrations can be obtained with BBUP across a wide dose range in a shorter time than other (eg, transdermal) dosage forms."( Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.
Bai, SA; Finn, A; Xiang, Q, 2016
)
0.43
"" Dose titration resulted in similar maintenance dosing (10."( Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study.
Baillie, S; Beavan, P; Bell, J; Bogdanowicz, K; Keen, J; Knight, A; Reed, K; Strang, J; van der Waal, R, 2017
)
0.46
"" In supervised dosing contexts, rapidly disintegrating formulations may enable wider buprenorphine prescribing."( Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study.
Baillie, S; Beavan, P; Bell, J; Bogdanowicz, K; Keen, J; Knight, A; Reed, K; Strang, J; van der Waal, R, 2017
)
0.46
" To optimize BUP's dosing regimen during pregnancy with better efficacy and safety, it is important to understand how pregnancy affects NBUP disposition."( Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation.
Bhatt, DK; Gao, C; Han, LW; Liao, MZ; Mao, Q; Neradugomma, NK; Phillips, BR; Prasad, B; Shen, DD, 2018
)
0.8
" This model will allow optimization of dosing strategies in future clinical trials."( The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome.
Adeniyi-Jones, SC; Ehrlich, ME; Fang, WB; Gastonguay, MR; Kraft, WK; Moody, DE; Moore, JN; Ng, CM, 2018
)
0.48
"6 ng/ml, respectively), suggesting a clinically relevant dosing regimen."( In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome.
Alund, AW; Brents, LK; Cabanlong, CV; Caperton, CO; Fantegrossi, WE; Griffin, BA; Martins, BS; Moran, JH; Owens, SM; Patton, AL; Russell, LN; Urquhart, KR; Wilson, CD; Zita, MD, 2019
)
0.83
" In addition, the dosing frequency of BUP study 2 participants was not restricted to twice-daily dosing."( Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine.
Bastian, JR; Caritis, SN; Chaphekar, N; Chen, H; Shaik, IH; Venkataramanan, R; Zhang, H; Zhao, W, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenanthrenesAny benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A3Homo sapiens (human)Km19.00007.34007.34007.3400AID624632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
bile acid secretionUDP-glucuronosyltransferase 1A3Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
retinoic acid bindingUDP-glucuronosyltransferase 1A3Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulumUDP-glucuronosyltransferase 1A3Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A3Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID624632Drug glucuronidation reaction catalyzed by human recombinant UGT1A32005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624620Specific activity of expressed human recombinant UGT2B7H2000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624621Specific activity of expressed human recombinant UGT2B7Y2000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (156)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (1.92)18.7374
1990's17 (10.90)18.2507
2000's44 (28.21)29.6817
2010's77 (49.36)24.3611
2020's15 (9.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials22 (13.33%)5.53%
Reviews4 (2.42%)6.00%
Case Studies8 (4.85%)4.05%
Observational1 (0.61%)0.25%
Other130 (78.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]